Insulet

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insulet 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. 

CEO
Ashley A. McEvoy
CEOAshley A. McEvoy
Employees
3,900
Employees3,900
Headquarters
Acton, Massachusetts
HeadquartersActon, Massachusetts
Founded
2000
Founded2000
Employees
3,900
Employees3,900

PODD Key Statistics

Market cap
21.06B
Market cap21.06B
Price-Earnings ratio
85.94
Price-Earnings ratio85.94
Dividend yield
Dividend yield
Average volume
703.24K
Average volume703.24K
High today
$299.48
High today$299.48
Low today
$292.77
Low today$292.77
Open price
$293.92
Open price$293.92
Volume
124.36K
Volume124.36K
52 Week high
$354.88
52 Week high$354.88
52 Week low
$230.05
52 Week low$230.05

Stock Snapshot

Insulet(PODD) stock is priced at $299.40, giving the company a market capitalization of 21.06B. It carries a P/E multiple of 85.94.

As of 2025-12-10, Insulet(PODD) stock has fluctuated between $292.77 and $299.48. The current price stands at $299.40, placing the stock +2.3% above today's low and -0.0% off the high.

Insulet(PODD) shares are trading with a volume of 124.36K, against a daily average of 703.24K.

In the last year, Insulet(PODD) shares hit a 52-week high of $354.88 and a 52-week low of $230.05.

In the last year, Insulet(PODD) shares hit a 52-week high of $354.88 and a 52-week low of $230.05.

PODD News

Simply Wall St 5d
FDA Clearance Of Lower-Target Omnipod 5 Upgrade Could Be A Game Changer For Insulet

Insulet Corporation recently received FDA 510(k) clearance for major enhancements to its Omnipod 5 Automated Insulin Delivery System, including a new 100 mg/dL...

FDA Clearance Of Lower-Target Omnipod 5 Upgrade Could Be A Game Changer For Insulet
TipRanks 6d
Insulet gets FDA clearance for updates to Omnipod 5 Automated Insulin Delivery

Insulet (PODD) announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to...

Simply Wall St 6d
Insulet: Assessing Valuation After Recent Share Price Cooldown

Advertisement Insulet stock reaction to recent performance Insulet (PODD) has quietly slipped over the past week and month, even though shares are still up so...

Insulet: Assessing Valuation After Recent Share Price Cooldown

Analyst ratings

90%

of 29 ratings
Buy
89.7%
Hold
10.3%
Sell
0%

People also own

Based on the portfolios of people who own PODD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.